Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder. The company manufactures continuous ...

Chief executive Mick Farrell says he’s confident the medical device company’s exports from Australia and Singapore will not ...

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder. The company manufactures continuous ...

Analysts have provided ResMed with 5 ratings, resulting in a consensus rating of Outperform. The average one-year price ...

The Breas Z2 Auto is a good option for travelers who value simplicity. The machine comes with a bunch of accessories right in ...

In the assessment of 12-month price targets, analysts unveil insights for ResMed, presenting an average target of $267.0, a ...

Resmed (RMD) announced its home sleep apnea test, NightOwl, is now available across the United States. NightOwl is an FDA-cleared home sleep ...

ResMed shares have been caught up in the recent market volatility. Has this created a buying window for ResMed shares?

Sleep patient volume growth was slower in the last 12 months but is expected to improve in the next 12 months, according to the 1Q25 HME Sleep and Oxygen Survey from Needham.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing ...